Negative immunoregulatory effects of noradrenaline through alpha2-adrenoceptor activation
Related Experiment Video
Updated: Sep 6, 2026

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors
Published on: June 7, 2016
Michael Maes1, Aihua Lin, Gunter Kenis
1Department of Psychiatry & Neuropsychology, University Hospital of Maastricht, the Netherlands. crc-mh@online.be
Abstract:
BACKGROUND: There are some reports that catecholamines and beta-adrenoceptor agonists may suppress some immune functions. OBJECTIVES: The present study was carried out in order to examine the effects of noradrenaline (10-5 M, 10-6 M and 10-7 M), yohimbine (10-5 M, 10-6 M and 10-7 M), an alpha2-adrenoceptor antagonist, and clonidine (105 M, 10-6 M and 10-7 M), an alpha2-adrenoceptor agonist, on the stimulated production of interferon-gamma (IFNgamma), a pro-inflammatory cytokine, and interleukin-10 (IL-10), an immuno-inhibitory cytokine. DESIGN: We measured the in vitro production of IFNgamma and IL-10 by stimulated, diluted whole blood of 16 normal volunteers. The IFNgamma/IL-10 production ratio was computed since this ratio reflects the pro- versus anti-inflammatory capacity of the cultured whole blood. RESULTS: We found that 1) noradrenaline, 10-5 M, 10-6 M, and 10-7 M, significantly suppressed the production of IFNgamma and that noradrenaline, 10-5 M, significantly enhanced the production of IL-10. Clonidine, 10-5 M and 10-7 M, significantly suppressed the production of IFNgamma. Noradrenaline, 10-5 M and 10-6 M, and clonidine, 10-5 M, significantly suppressed the IFNgamma/IL-10 production ratio. There were no significant effects of yohimbine on IFNgamma or IL-10 production. CONCLUSIONS: 1) noradrenaline has significant negative immunoregulatory effects in humans through enhancing the production of IL-10 and suppressing that of IFNgamma; and 2) the suppression of the production of IFNgamma is in part related to alpha2-adrenoceptor activation.
More Related Videos
Related Concept Videos
Adrenergic Neurons: Neurotransmission
Synthesis: Catecholamine synthesis requires tyrosine, which is taken...
Adrenergic Receptors (Adrenoceptors): Classification
α-Adrenoceptors
α-Adrenoceptors are classified into two main subtypes: α1 and α2. The α1 adrenoceptors, which are found on postsynaptic...
Adrenergic Receptors: ɑ Subtype
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase C—inositol-1,4,5-trisphosphate...
Adrenergic Receptors: β Subtype
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors have equal affinities for...
Adrenergic Agonists: Therapeutic Uses
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and anaphylaxis:...
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally, α1-blockers effectively address urinary obstruction...

